Geron is seeking partners with the technical and financial resources to enable further development of its stem cell programs. “Our employees, collaborators and shareholders can be proud of the pioneering role they have played to advance our stem cell technology into the clinic,” said Dr. Scarlett. “Stem cells continue to hold great medical promise. We believe that our leadership role in the field and the quality of our stem cell assets — which are widely recognized as being among the most innovative, comprehensive and advanced cell therapy programs in the world — will be an important point of differentiation in our discussions to partner these assets.” In order to facilitate transfer of these programs to partners, Geron will retain a core group of employees from its stem cell operations through the end of the second quarter of 2012.
Geron plans to close the GRNOPC1 trial for spinal cord injury to further enrollment, although it will continue to follow all enrolled patients, accruing data and updating FDA and the medical community on their progress. In this trial, GRNOPC1 has been well tolerated with no serious adverse events.
Conference Call Information
Geron’s Chief Executive Officer, John A. Scarlett, M.D., will host a conference call for analysts and investors to discuss changes to the Company’s business on Tuesday, November 15, 2011 at 6:00 a.m. Pacific Time, 9:00 a.m. Eastern Time.Participants can access the conference call live via telephone by dialing 866-510-0705 (U.S.); 617-597-5363 (international). The passcode is 64257143. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available at http://www.media-server.com/m/p/92t2mq67. The audio webcast of the conference call will be available for online replay approximately one hour following the live broadcast through November 30, 2011. About Geron’s Oncology Programs Telomerase Inhibitor Program Geron’s proprietary nucleic acid chemistry platform is being used to generate potent and specific inhibitors of telomerase, an enzyme necessary for the indefinite replicative capacity of many cancers and cancer stem cells. Imetelstat, the Company's lead drug candidate in this program, is being evaluated in two randomized Phase 2 studies, one in metastatic breast cancer, and the other in advanced non-small cell lung cancer. These indications represent two of the leading causes of death from malignancy worldwide. Imetelstat is also being evaluated in a Phase 2 study of essential thrombocythemia, a myeloproliferative neoplasm, and in a Phase 2 study of multiple myeloma. Geron expects top-line data from these four Phase 2 trials to be available before the end of the fourth quarter of 2012.